OpenBilldrug price receipt

NADAC week of 2026-10-14

BIMZELX 320 MG/2 ML AUTOINJECT

FDA nonproprietary name: bimekizumab

For 2 mL

Pharmacies pay

$16,032.07 filed

2 × $8,016.03643 per ML

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$14,515.88 filed

2 × $7,257.94095 per ML, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

0.91× estimated

Medicare paid 9% less than pharmacies pay.

Part D averages every strength and form sold under “Bimzelx Autoinjector” / “Bimekizumab-Bkzx” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$18,441.88 estimated

$16,032.07 + $2,404.81 (15%) + $5.00 fee per fill = $18,441.88

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

BIMZELX 320 MG/2 ML AUTOINJECT is how the CMS NADAC file names this product. The FDA NDC Directory lists it as bimekizumab, under the trade name “Bimzelx”.

FDA gives its dosage form as injection, solution and its route as subcutaneous.

The labeler, the company named on the label, is UCB, Inc.

FDA lists no Established Pharmacologic Class for it.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 50474-0782-84.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $16,032.07 for 2 mL (2 × $8,016.03643 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

The NDC

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name bimekizumab with BIMZELX 320 MG/2 ML AUTOINJECT.

ProductPharmacies pay per unitMedicare per unit
BIMZELX 160 MG/ML AUTOINJECTOR
brand · injection, solution
$8,035.07333 to $8,112.5853 per ML filed
eff. 2026-01-01 to 2026-09-23
$7,257.94095 per ML filed
Part D 2024 average
BIMZELX 320 MG/2 ML AUTOINJECT this page
brand · injection, solution
$8,016.03643 per ML filed
eff. 2026-09-23
$7,257.94095 per ML filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

What Medicare paid

Medicare Part D paid $14,515.88 for 2 mL, at an average of $7,257.94095 per ML in 2024 (2024-01-01 to 2024-12-31) for “Bimzelx Autoinjector” and “Bimekizumab-Bkzx”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 5,294 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for BIMZELX 320 MG/2 ML AUTOINJECT labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Bimzelx Autoinjector / Bimekizumab-Bkzx: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's ML. Joined on brand name.
Why does this page start at 2 mL?
NADAC prices this product per ML. The FDA NDC Directory’s package description gives 2 mL in one package for this product’s NDC (“1 SYRINGE, GLASS in 1 CARTON (50474-782-84) / 2 mL in 1 SYRINGE, GLASS”), so the card starts at one package: 2 ML. Change it to match your prescription.